Merck and Moderna to File Personalized mRNA Melanoma Vaccine With FDA

Merck and Moderna are preparing an FDA filing for a personalized mRNA melanoma vaccine given alongside Keytruda, after reading out Phase 3 results. The companies disclosed the filing plan through Medical Daily's reporting. For dermatologists who treat advanced melanoma, the news moves a much-discussed combination one step closer to a regulatory decision.

The candidate is an individualized neoantigen therapy. It's built from a patient's own tumor mutations, then delivered as mRNA. The partner drug is pembrolizumab, Merck's anti-PD-1 checkpoint inhibitor already standard in melanoma care.

What does the Phase 3 readout mean?

The sponsors say results from the Phase 3 study support moving to a regulatory submission. Medical Daily's report did not publish hazard ratios, recurrence-free survival figures or the trial's full design, and Derm Field will report those numbers when the companies release them.

What's confirmed is the trajectory. The program has now cleared the Phase 3 evidence bar the companies set for filing. That alone distinguishes it from most cancer-vaccine efforts, which have stalled in earlier phases.

Who would the combination be for?

Melanoma remains the deadliest form of skin cancer, and the vaccine is being developed for patients whose disease is managed with Keytruda. The reporting did not specify the exact stage of disease targeted in the filing — earlier reporting on this program has focused on resected, high-risk melanoma, but Derm Field could not confirm the indication scope from this source.

Skin cancer terminology matters here. Any eventual label will hinge on AJCC staging and recurrence data, and dermatologists should watch for those specifics in the sponsor's release.

Why the Merck–Moderna pairing matters

The collaboration pairs two of the biggest names in their fields. Moderna brings the mRNA platform proven at scale during the pandemic. Merck brings Keytruda, one of the best-selling oncology drugs in the world.

A personalized vaccine plus checkpoint blockade is the combination oncology has chased for years. If approved, it would be among the first individualized mRNA cancer immunotherapies to reach the market.

What happens next

The immediate next step is the FDA submission itself. Timing for the filing wasn't disclosed in the reporting.

After filing comes review, then — if all goes well — a decision that could reshape adjuvant melanoma treatment. Derm Field will track the submission, the data behind it, and any advisory committee dates as they emerge.